This page lists ClinicalTrials.gov records that name Setmelanotide among their listed interventions. Titles, phases, and status are taken from the official registry. It is a research reference only. It is not medical advice, and it does not offer or recommend any product for human or veterinary use.
Search
Compound
All compounds
Setmelanotide
Phase
All phases
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Observational
Not applicable
Expanded access
Status
All statuses
No registered studies match that search or filter.
Enrolling by invitation Phase 2 Setmelanotide
NCT ID NCT07496463
Sponsor Massachusetts General Hospital
Registry dates 2026-07-21 – 2027-04-30
Enrollment 1 registered participants
Locations United States
Conditions listed Pseudohypoparathyroidism Type 1a; Obesity Registry record on ClinicalTrials.gov
Recruiting Phase 3 Setmelanotide
NCT ID NCT06760546
Sponsor Rhythm Pharmaceuticals, Inc.
Registry dates 2025-09-23 – 2028-03-13
Enrollment 39 registered participants
Locations United States, United Kingdom
Conditions listed Hypothalamic Obesity; Multiple Pituitary Hormone Deficiency Genetic Form; Septo-Optic Dysplasia; Optic Nerve Hypoplasia +2 more Registry record on ClinicalTrials.gov
Active, not recruiting Phase 2 Setmelanotide
NCT ID NCT06772597
Sponsor Rhythm Pharmaceuticals, Inc.
Registry dates 2025-03-04 – 2030-10-30
Enrollment 18 registered participants
Locations United States
Conditions listed Prader-Willi Syndrome; Obesity; Hyperphagia Registry record on ClinicalTrials.gov
Completed Phase 3 Setmelanotide
NCT ID NCT06596135
Sponsor Rhythm Pharmaceuticals, Inc.
Registry dates 2024-10-21 – 2026-06-24
Enrollment 28 registered participants
Locations United States
Conditions listed Obesity Associated With Defects in Leptin-melanocortin Pathway Registry record on ClinicalTrials.gov
Active, not recruiting Phase 3 Setmelanotide Results posted
NCT ID NCT05774756
Sponsor Rhythm Pharmaceuticals, Inc.
Registry dates 2023-04-26 – 2027-04-16
Enrollment 143 registered participants
Locations United States, Canada, Germany +3 more
Conditions listed Hypothalamic Obesity Registry record on ClinicalTrials.gov
Recruiting Phase 4 Setmelanotide
NCT ID NCT07674290
Sponsor Tom Hühne
Registry dates 2023-01-01 – 2030-12-31
Enrollment 200 registered participants
Locations Germany
Conditions listed Bardet Biedl Syndrome (BBS); Bardet Biedl Syndrome; Bardet-Biedl Syndrome (BBS); Alstrom Syndrome Registry record on ClinicalTrials.gov
Completed Phase 3 Setmelanotide Results posted
NCT ID NCT05093634
Sponsor Rhythm Pharmaceuticals, Inc.
Registry dates 2022-04-26 – 2026-06-30
Enrollment 296 registered participants
Locations United States, Canada, France +7 more
Conditions listed Obesity; Genetic Obesity Registry record on ClinicalTrials.gov
Completed Phase 3 Setmelanotide Results posted
NCT ID NCT04966741
Sponsor Rhythm Pharmaceuticals, Inc.
Registry dates 2022-03-08 – 2024-11-08
Enrollment 12 registered participants
Locations United States, Australia, Spain +1 more
Conditions listed Bardet-Biedl Syndrome; POMC Deficiency Obesity; PCSK1 Deficiency Obesity; LEPR Deficiency Obesity Registry record on ClinicalTrials.gov
Completed Phase 3 Setmelanotide Results posted
NCT ID NCT05194124
Sponsor Rhythm Pharmaceuticals, Inc.
Registry dates 2021-12-21 – 2023-10-19
Enrollment 19 registered participants
Locations United States, Canada, Germany +3 more
Conditions listed Bardet-Biedl Syndrome; POMC Deficiency Registry record on ClinicalTrials.gov
Completed Phase 2 Setmelanotide Results posted
NCT ID NCT04963231
Sponsor Rhythm Pharmaceuticals, Inc.
Registry dates 2021-11-30 – 2024-09-30
Enrollment 164 registered participants
Locations United States, Canada, Germany +5 more
Conditions listed Genetic Obesity Registry record on ClinicalTrials.gov
Completed Phase 4 Setmelanotide Results posted
NCT ID NCT05046132
Sponsor Rhythm Pharmaceuticals, Inc.
Registry dates 2021-08-05 – 2022-04-07
Enrollment 77 registered participants
Locations United States
Conditions listed Healthy Registry record on ClinicalTrials.gov
Completed Phase 2 Setmelanotide Results posted
NCT ID NCT04725240
Sponsor Rhythm Pharmaceuticals, Inc.
Registry dates 2021-06-07 – 2022-06-28
Enrollment 18 registered participants
Locations United States
Conditions listed Hypothalamic Obesity Registry record on ClinicalTrials.gov
Completed Phase 1 Setmelanotide
NCT ID NCT04348175
Sponsor Rhythm Pharmaceuticals, Inc.
Registry dates 2020-07-09 – 2021-04-17
Enrollment 32 registered participants
Locations United States
Conditions listed Renal Insufficiency Registry record on ClinicalTrials.gov
Completed Phase 3 Setmelanotide Results posted
NCT ID NCT03746522
Sponsor Rhythm Pharmaceuticals, Inc.
Registry dates 2018-11-23 – 2021-03-08
Enrollment 52 registered participants
Locations United States, Canada, France +3 more
Conditions listed Bardet Biedl Syndrome (BBS); Alström Syndrome (AS) Registry record on ClinicalTrials.gov
Completed Phase 2, Phase 3 Setmelanotide Results posted
NCT ID NCT03651765
Sponsor Rhythm Pharmaceuticals, Inc.
Registry dates 2018-07-15 – 2025-01-09
Enrollment 205 registered participants
Locations United States, Canada, France +5 more
Conditions listed Obesity Associated With Defects in Leptin-melanocortin Pathway Registry record on ClinicalTrials.gov
Completed Phase 3 Setmelanotide Results posted
NCT ID NCT03287960
Sponsor Rhythm Pharmaceuticals, Inc.
Registry dates 2018-01-30 – 2020-09-25
Enrollment 15 registered participants
Locations Canada, France, Germany +3 more
Conditions listed Leptin Receptor Deficiency Obesity Registry record on ClinicalTrials.gov
Completed Phase 2 Setmelanotide
NCT ID NCT03262610
Sponsor Rhythm Pharmaceuticals, Inc.
Registry dates 2017-08-15 – 2018-01-31
Enrollment 1 registered participants
Locations United States
Conditions listed Hypertriglyceridemia; Obesity Registry record on ClinicalTrials.gov
Completed Phase 3 Setmelanotide Results posted
NCT ID NCT02896192
Sponsor Rhythm Pharmaceuticals, Inc.
Registry dates 2017-02-14 – 2020-05-25
Enrollment 15 registered participants
Locations United States, Belgium, Canada +4 more
Conditions listed Pro-opiomelanocortin (POMC) Deficiency Obesity Registry record on ClinicalTrials.gov
Completed Phase 2 Setmelanotide Results posted
NCT ID NCT03013543
Sponsor Rhythm Pharmaceuticals, Inc.
Registry dates 2017-02-10 – 2022-03-01
Enrollment 213 registered participants
Locations United States, Canada, France +6 more
Conditions listed Genetic Obesity; Obesity; Obesity Due to Melanocortin 4 Receptor Deficiency Registry record on ClinicalTrials.gov
Completed Phase 2 Setmelanotide Results posted
NCT ID NCT02311673
Sponsor Rhythm Pharmaceuticals, Inc.
Registry dates 2015-03-19 – 2016-10-26
Enrollment 40 registered participants
Locations United States
Conditions listed Prader-Willi Syndrome Registry record on ClinicalTrials.gov
Unknown status Phase 2 Setmelanotide
NCT ID NCT02507492
Sponsor Charite University, Berlin, Germany
Registry dates 2015-01 – 2018-07
Enrollment 10 registered participants
Locations Germany
Conditions listed Homozygous or Compound Heterozygous POMC, LEPR or PCSK1 Gene Mutation Registry record on ClinicalTrials.gov
Completed Phase 1, Phase 2 Setmelanotide Results posted
NCT ID NCT02041195
Sponsor Rhythm Pharmaceuticals, Inc.
Registry dates 2014-01 – 2014-12
Enrollment 99 registered participants
Locations United States
Conditions listed Overweight and Obesity Registry record on ClinicalTrials.gov
Completed Phase 1 Setmelanotide
NCT ID NCT01867437
Sponsor Rhythm Pharmaceuticals, Inc.
Registry dates 2013-05 – 2014-03
Enrollment 15 registered participants
Locations United States
Conditions listed Obesity; Morbid Obesity Registry record on ClinicalTrials.gov
Completed Phase 2 Setmelanotide Results posted
NCT ID NCT01749137
Sponsor Rhythm Pharmaceuticals, Inc.
Registry dates 2013-01-14 – 2013-09-28
Enrollment 74 registered participants
Locations United States
Conditions listed Overweight Registry record on ClinicalTrials.gov
Completed Phase 1 Setmelanotide
NCT ID NCT02431442
Sponsor Rhythm Pharmaceuticals, Inc.
Registry dates 2012-01 – 2014-01
Enrollment 57 registered participants
Conditions listed Overweight; Obese Registry record on ClinicalTrials.gov